Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 4/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24508364 | 0.84 | KDM4E (0.73) | CYP2A13SIGMAR1KDM4ETDP1ALDH1A1 | |
| SCHEMBL4243681 | 0.83 | CYP2A13 (0.71) | CYP2A13KDM4ETDP1CYP2C9ALOX15 | |
| SCHEMBL9424160 | 0.83 | CYP2A13 (0.71) | CYP2A13SIGMAR1KDM4ETDP1ALDH1A1 | |
| SCHEMBL10714370 | 0.83 | CYP2A13 (0.71) | CYP2A13KDM4EALDH1A1CYP2C9ALOX15 | |
| SCHEMBL30900092 | 0.83 | CYP2A13 (0.71) | CYP2A13SIGMAR1KDM4ETDP1ALDH1A1 | |
| SCHEMBL110887 | 0.83 | CYP2A13 (0.71) | CYP2A13SIGMAR1ALDH1A1CYP2C9ALOX15 | |
| SCHEMBL11961576 | 0.83 | CYP2A13 (0.71) | CYP2A13KDM4ETDP1CYP2C9ALOX15 | |
| SCHEMBL4264928 | 0.83 | CYP2A13 (0.71) | CYP2A13SIGMAR1KDM4ETDP1ALDH1A1 | |
| SCHEMBL27899087 | 0.83 | CYP2A13 (0.71) | CYP2A13SIGMAR1KDM4EALDH1A1CYP2C9 | |
| SCHEMBL30596611 | 0.82 | KDM4E (0.71) | CYP2A13SIGMAR1KDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598165-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2013-12-03 | — | — | US | claimed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | claimed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-8598165-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2013-12-03 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | CYP1A2, CYP2D6, CYP1A1 | CYP2A13 6/4885SIGMAR1 610/4885KDM4E 2221/4885 |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | CYP1A2, CYP2D6, CYP1A1 | CYP2A13 6/4885SIGMAR1 610/4885KDM4E 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.